Abstract
Several studies have suggested associations between MDM2 (mouse double minute 2 homolog) polymorphisms and leukemia risk, but they reported contradictory results. For better understanding of the effect of MDM2 T309G polymorphism on leukemia risk, we performed a meta-analysis. All eligible studies were identified through a search of PubMed, Web of Science, EMBASE, and Chinese Biomedical Literature (CBM) databases before May 2014. Assessment of associations between the MDM2 T309G polymorphism and leukemia risk was conducted by odds ratios (ORs) and 95% confidence intervals (95% CIs). Finally, a total of 11 publications covering 12 case-control studies with 2, 362 cases and 5, 562 controls concerning MDM2 T309G polymorphism with respect to leukemia were included in the meta-analysis. Significant associations were found between MDM2 T309G polymorphism and leukemia risk in four models in overall populations (G vs T: OR=1.29, 95% CI=1.11- 1.49, p=0.001; GG vs TT: OR=1.67, 95% CI=1.21-2.30, p=0.002; GG vs TG/TT: OR=1.56, 95% CI=1.21-2.00, p=0.001; GG/TG vs TT: OR=1.28, 95% CI=1.05-1.57, p=0.015). In the sub-group analysis according to ethnicity, increased leukemia risks were observed in three genetic models among Asians but not Caucasians. In conclusion, the results of our meta-analysis suggest that the MDM2 T309G polymorphism can increase the risk of leukemia, especially among Asian populations.
Highlights
Leukemia is a common malignant disease of hematopoietic systems, it is a malignant tumor of the hematopoietic system and cause by unbalanced hematopoietic cells proliferation and death, uncontrolled differentiation disorder, disruption and other mechanisms of apoptosis in the bone marrow and other hematopoietic tissues proliferate accumulation and infiltration of other tissues and organ (Estey, 2001; Jiang et al, 2014; Yan et al, 2014)
Based on the speed of disease progression, leukemia can be divided into acute leukemia and chronic leukemia, while acute leukemia can be subdivided into acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) according to cytogenetic analysis (Yan et al, 2014; Yan et al, 2014), chronic leukemia can be divide into chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) (Jiang et al, 2014)
Study characteristics According to the inclusion criteria defined above, a total of publications (Ellis et al, 2008; Phang et al, 2008; Zenz et al, 2008; Chen et al, 2009; Do et al, 2009; Xiong et al, 2009; Phillips et al, 2010; Dong et al, 2012; Ebid et al, 2012; Chen et al, 2013; Liu et al, 2013) containing case-control studies with 2362 cases and 5562 controls concerning MDM2 T309G polymorphism with respect to leukemia were included in the metaanalysis
Summary
Leukemia is a common malignant disease of hematopoietic systems, it is a malignant tumor of the hematopoietic system and cause by unbalanced hematopoietic cells proliferation and death, uncontrolled differentiation disorder, disruption and other mechanisms of apoptosis in the bone marrow and other hematopoietic tissues proliferate accumulation and infiltration of other tissues and organ (Estey, 2001; Jiang et al, 2014; Yan et al, 2014). The MDM2 protein plays a critical role in the regulation of p53 protein stability and functional, it regulates p53 activity through a negative feedback loop (Poyurovsky et al, 2010). The polymorphism of MDM2 T309G is suggested to be associated with the risk of various human cancers (Peng et al, 2013; Chen et al, 2014; Chen et al, 2014; Gao et al, 2014; Tang et al, 2014; Wang et al, 2014). Results concerning the relationship between MDM2 T309G polymorphism and leukemia risk were different or even contradictory
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Pacific journal of cancer prevention : APJCP
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
